DDIT3 Antibodies

Structure of DDIT3

DDIT3 is an intranuclear protein with a molecular weight of approximately 19 kDa. There are slight variations among different species due to differences in amino acid sequences.

The DDIT3 protein contains 169 amino acids and its structure includes a characteristic leucine zipper domain. This domain forms an heterodimer with members of the C/EBP family and mediates specific DNA binding. The N-terminal of the protein is a transcriptional activation domain, rich in acidic amino acids; the C-terminal is the basic region and the zipper region, responsible for dimerization and DNA binding. DDIT3 is expressed at extremely low levels under normal conditions. When endoplasmic reticulum stress occurs, its expression rapidly increases. It inhibits the transcription of genes regulated by C/EBP, causing cell cycle arrest or apoptosis. Phosphorylation modification is crucial for its transcriptional activity. Multiple sites of modification can enhance protein stability and regulate its nuclear translocation.

Fig. 1 Diagram of the predicted fusion protein SMARCA2::DDIT3.¹

Key structural properties of DDIT3:

• Characteristic leucine zipper domain
• C-terminal basic DNA-binding domain
• N-terminal acidic transcriptional activation domain
• Dimerization interface mediates hetero-complex formation with C/EBP proteins

Functions of DDIT3

The core function of DDIT3 is to regulate cell fate under endoplasmic reticulum stress. Additionally, it is involved in various physiological processes such as adipocyte differentiation, hematopoietic regulation, and inflammatory responses.

The expression of DDIT3 remains at an extremely low level under normal physiological conditions, but is rapidly induced and upregulated during endoplasmic reticulum stress. Its transcriptional activation depends on the direct interaction of ATF4 and ATF6, and its protein activity is precisely regulated by phosphorylation modifications.

Applications of DDIT3 and DDIT3 Antibody in Literature

1. Shah, Ahmed, et al. "Novel SMARCA2:: DDIT3 Fusion in Primary Subcutaneous Myxoid Liposarcoma due to an Unusual Unbalanced Chromosomal Translocation." Genes, Chromosomes and Cancer 64.10 (2025): e70089. https://doi.org/10.1002/gcc.70089

This article reports a case of a 26-year-old male with a myxoid liposarcoma. The tissue morphology is typical, but there is a novel SMARCA2::DDIT3 gene fusion. The study found that this fusion retains the key functional domains of DDIT3, further confirming that the classic pathological morphology can guide molecular testing to reveal new variations.

2. Du, Mengbao, et al. "C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription." Journal of Experimental & Clinical Cancer Research 43.1 (2024): 79. https://doi.org/10.1186/s13046-024-02975-3

The study found that the imbalance in the ratio of the two subtypes of C/EBPα (p42/p30) affects the endoplasmic reticulum stress response in AML by regulating DDIT3. Patients with a low p42/p30 ratio are resistant to BCL2 inhibitors when used alone, but this resistance can be overcome by combining with endoplasmic reticulum stress inducers.

3. Ranji, Parmida, et al. "Deciphering the role of FUS:: DDIT3 expression and tumor microenvironment in myxoid liposarcoma development." Journal of Translational Medicine 22.1 (2024): 389. https://doi.org/10.1186/s12967-024-05211-w

In this study, using a decellularized sarcoma model, it was found that the microenvironment of myxoid liposarcoma (MLS) jointly regulates the tumor phenotype with the FUS::DDIT3 fusion gene, and this fusion gene is a key factor determining its preadipocyte differentiation.

4. Berastegui, Nerea, et al. "The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes." Nature Communications 13.1 (2022): 7619. https://doi.org/10.1038/s41467-022-35192-7

Studies have confirmed that the transcription factor DDIT3 is specifically highly expressed in hematopoietic stem cells of MDS patients and is a key factor driving the failure of red blood cell production. Targeted inhibition of DDIT3 can restore red blood cell differentiation, suggesting that it could serve as a new therapeutic target for MDS.

5. Jauhiainen, Alexandra, et al. "Distinct cytoplasmic and nuclear functions of the stress induced protein DDIT3/CHOP/GADD153." PloS one 7.4 (2012): e33208. https://doi.org/10.1371/journal.pone.0033208

The study found that the transcription factor DDIT3 regulates target genes through differential cellular localization (cytoplasmic or nuclear). Cytoplasmic DDIT3 mainly inhibits cell migration, while nuclear DDIT3 induces cell cycle arrest. Its mechanism of action depends on heterodimerization with different transcription factors.

Creative Biolabs: DDIT3 Antibodies for Research

Creative Biolabs specializes in the production of high-quality DDIT3 antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom DDIT3 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our DDIT3 antibodies, custom preparations, or technical support, contact us at email.